ANAC Arctos NorthStar Acquisition Corp. Class A
DELISTED - Anacor Pharmaceuticals Inc is a United States-based biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company's product candidates include topically administered dermatologic compounds-tavaborole (formerly AN2690), a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory for the treatment of atopic dermatitis and psoriasis. In addition, it is engaged in the development of other wholly-owned clinical product candidates, AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. The Company's clinical pipeline also includes internally developed topical and systemic boron-based compounds in development.
$10.19 0.00 (0.00%)
As of 02/24/2023 00:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Small cap
GICS sector: Financials
Industry: Shell Companies
Index country: USA
Country of incorporation:
IPO date: 04/15/2021
Outstanding shares: 31,625,000
Average volume: 705
Market cap: $322,258,750
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%